



PATENT
ATTENTION: MS AFTER FINAL
RESPONSE UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE REQUESTED
EXAMINING GROUP 1600

Confirmation no. 3131
Atty. Dkt. No. 087147-0494 (new)
Atty. Dkt. No. 087147-0450 (old)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re reissue application of: U.S. Pat. No. 6,348,481, issued February 19, 2002

Applicants: Yoshiyuki INADA, et al.

Title: PHARMACEUTICAL COMPOSITION FOR ANGIOTENSIN II-
MEDIATED DISEASES

Appl. No.: 10/781,263

Filing Date: 02/19/2004

Examiner: Deborah C. Lambkin

Art Unit: 1626

REQUEST FOR CORRECTION OF FILING RECEIPT

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please correct the Filing Receipt as follows:

1. Under "Foreign Applications" add Japanese Patent 135524-1993, filed
06/07/1993.

2. Please change the "Atty Docket No." to -087147-0494--.


A copy of the Filing Receipt, with the corrections noted in red ink, is attached.

Application No. 10/781,263
Response to Office action dated August 22, 2005
Atty. Dkt. No. 087147-0494 (new)
Atty. Dkt. No. 087147-0450 (old)

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date Feb. 22, 2006

By 

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicants
Registration No. 35,264



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/781,263	02/19/2004	1614	942	087147-0450 087147-0494		10	3

CONFIRMATION NO. 3131

22428
FOLEY AND LARDNER
SUITE 500
3000 K STREET NW
WASHINGTON, DC 20007

FILING RECEIPT



OC000000012570139

Date Mailed: 05/07/2004

Receipt is acknowledged of this reissue Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Yoshiyuki Inada, Kawanishi, JAPAN;
Keiji Kubo, Osaka, JAPAN;

Domestic Priority data as claimed by applicant

This application is a REI of 09/758,355 01/12/2001 PAT 6,348,481
which is a DIV of 09/563,855 05/04/2000 PAT 6,228,874
which is a CON of 09/287,167 04/06/1999 ABN
which is a CON of 08/883,040 06/26/1997 PAT 5,958,961
which is a DIV of 08/351,011 12/07/1994 PAT 5,721,263
which is a CIP of 08/254,541 06/06/1994 ABN

Foreign Applications

Japanese Patent 135524-1993, filed 06/07/1993

If Required, Foreign Filing License Granted: 05/07/2004

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

Title

Pharmaceutical composition for angiotensin II-mediated diseases

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).